Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429113 | 0.91 | HPGD (0.57) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429161 | 0.88 | HPGD (0.54) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429212 | 0.87 | CYP1A2 (0.47) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429066 | 0.87 | KDM4E (0.50) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL3205961 | 0.87 | CYP1A2 (0.47) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429082 | 0.87 | CYP1A2 (0.47) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429062 | 0.87 | L3MBTL1 (0.60) | HPGDSMN1; SMN2CYP1A2CYP2C19TNKS2 | |
| SCHEMBL13429075 | 0.87 | CYP1A2 (0.56) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL13429129 | 0.87 | RHEB (0.50) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL3222448 | 0.85 | CYP1A2 (0.45) | HPGDHTTSMN1; SMN2MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960548-B2 | Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| EP-1883403-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | US ARMY, SECRETARY OF THE ARMY | 2007-04-05 | — | — | US | disclosed |
| WO-2006119148-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | FGFR1, FGFR3, MET | HPGD 1539/4885HTT 4392/4885SMN1; SMN2 4696/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | HPGD 2472/4885HTT 2427/4885SMN1; SMN2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.